11 Best Long Term Low Risk Stocks to Invest in

2. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

EPS next 5Y: 33.73%

Beta: 0.25

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) secures a spot on our list of 11 best long term low risk stocks to buy. Following the update on its ongoing clinical study, analysts are maintaining a Buy rating while raising the price target.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric disorders. Operating from its headquarters in California, the company gained U.S. approval for valbenazine (Ingrezza®) for tardive dyskinesia and markets treatments for Huntington’s chorea, adrenal hyperplasia, endometriosis, and uterine fibroids. The company’s comprehensive pipeline includes treatments for Parkinson’s, Tourette’s, and novel agents like NBI‑1117568 in schizophrenia trials.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the termination of its Phase 2 study on NBI-921352, an investigational drug, as of July 14, 2025. The company, with its tests, aimed to evaluate the safety and tolerability of the drug when used alongside other treatments for patients with SCN8A-DEE, a rare and severe neurological disorder. Phase 2 of the study involved assessing the drug’s ability to reduce seizure frequency in patients with SCN8A-DEE. As it failed to show a meaningful reduction, the study was terminated.

The company’s lead candidates continue to be crinecerfont for congenital adrenal hyperplasia (CAH), and NBI-1117568, a potential treatment for psychosis and cognitive disorders. Later, on July 21, 2025, Truist initiated coverage of the stock with a Buy rating and a price target of $163. On the other hand, Morgan Stanley, while maintaining the Buy rating, has raised the price target from $148 to $150.

Despite the trial setback, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) continues to show strong growth prospects with a 33.73% projected EPS increase and a low beta of 0.25.